EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial – 1)

A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination with Anticancer Treatments in Patients with Solid Malignancies

We are enrolling patients in our first clinical trial in multiple solid tumour indications. The trial is currently open in Australia, Spain and UK. Patients and caregivers can find details about this trial, including participating clinical trial sites, by clicking on the link below to the UK registry ISRCTN.

Discuss with your doctor whether participating in a clinical trial is right for you.

For patient inquiries, please contact enquiries@gwt.bio

For more information

More details about our Phase I/II clinical trial EMITT-1 can be found on link below to the
UK registry ISRCTN